ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

585
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
03 Oct 2025 11:10

Hong Kong Buybacks Weekly (Oct 3rd): Tencent, Anta, Hang Seng Bank

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
514 Views
Share
26 Sep 2025 10:36

Hong Kong Buybacks Weekly (Sep 26th): Tencent, Anta, Sinopec

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
579 Views
Share
25 Sep 2025 18:32

Microport Scientific Placement - Should Be Well-Flagged, Will Lift Overhang

Otsuka Holdings (4578 JP) aims to raise around US$150m via selling its remaining shares in Microport Scientific (853 HK). In this note, we run the...

Logo
497 Views
Share
21 Sep 2025 10:05

HK Connect Flows Weekly (Sep 19th): Alibaba, Beigene, China Pacific Insurance

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Alibaba, Beigene, China Pacific Insurance, Duality...

Logo
582 Views
Share
19 Sep 2025 10:16

Hong Kong Buybacks Weekly (Sep 19th): Tencent, Hang Seng Bank, Mgm China

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
492 Views
Share
x